Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 3Phase 1 3Phase 4 2Phase 2/3 2Phase 1/2 2Phase EARLY_PHASE1 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Gastrointestinal 2Dermatologic 2Tumor-Agnostic 1Plasma cell 1Gynecologic 1

Conditions

Melanoma 2

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × relatlimab × Dermatologic × Clear all
NCT07281924 2026-05-29

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

University of Wisconsin, Madison

Phase 1/2 Recruiting
15 enrolled
Dermatologic

Melanoma

NCT06683755 2024-11-12

Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡